KIT and gastrointestinal stromal tumor: This simultaneous approach has already demonstrated its success for IMT, which acts both in CML therapy (BCR-ABL1 inhibitor) and in gastrointestinal stromal tumor (GIST) (c-Kit inhibitor) therapy, making it attractive to the pharmaceutical industry in Research and Development (R&D).